Click the hypertext link to download copies of the HESI presentations.
Assembly of Members Session
Agricultural Chemical Safety Assessment Technical Committee (ACSA)
Prof. Alan R. Boobis, Imperial College London
Development and Application of Biomarkers of Toxicity Technical Committee
Ms. Syril Pettit, HESI
Technical Committee on Integration of Biomonitoring Exposure Data into the Risk Assessment Process
Ms. Nancy Doerrer, HESI
Cancer Hazard Identification Strategies Project Committee (CHIS)
Dr. James MacDonald, Schering-Plough Research Institute
Biological Significance of DNA Adducts Project Committee
Dr. Daniel Casciano, US FDA
Nanomaterial Environmental, Health, and Safety Project Committee
Dr. James Gibson, East Carolina University
Non-Clinical/Clinical Safety Correlations Technical Committee
Dr. James Sanders - Johnson & Johnson Pharmaceuticals
Protein Allergenicity Technical Committee
Dr. Laura Privalle - BASF, Inc.
Risk Assessment Methodology Technical Committee
Dr. Michelle Embry, HESI
PPAR Agonist Project Committee
Dr. James E. Klaunig, Indiana School of Medicine
Emerging Issues Session
Environmental Epigenomics and Disease
Dr. Randy L. Jirtle, Duke University Medical Center
Epigenetics and Imprinting in Human Health and Disease: Actions for HESI
Dr. Jay Goodman, Michigan State University
Approaches to Assess the Effects of Anthopogenic Chemicals in Fish
Dr. Nancy Denslow, University of Florida
Use of Ecotoxicogenomics to Understand Exposure and Effects of PPCPs in the Environment
Dr. Don Versteeg, The Procter & Gamble Company
Emergence of Animal Alternative Needs in Environmental Risk Assessment: Replacement of the Fist Acute Toxicity Test
Dr. Scott Belanger, The Procter & Gamble Company
Sensitive Populations Scientific Session
HESI Scientific Session Sensitive Populations
Dr. D. Gail McCarver, Medical College of Wisconsin
Use of PBPK Modeling and Toxicokinetics/Toxicodynamics (TK/TD) for Sensitive Populations and Life Stages
Dr. Hugh A. Barton, US EPA
Genetic Differences in Sensitive Populations
Dr. Ron Hines, Medical College of Wisconsin and Children’s Research Institute
Limitations & Challenges of Federal Regulations and Guidelines – A Pharmaceutical Industry Perspective
Dr. Gregg Cappon, Pfizer Inc.
Dr. Mark E. Hurt, Pfizer Inc.
Human Biomonitoring in Europe
Dr. R. Smolders, VITO
State of the Science Scientific Session
Cardiovascular Safety Project Committee 2001 to 2005 and
Proarrhythmia Models Project Committee 2005 to 2007
Dr. Alan Stuart Bass, Schering-Plough Research Institute
Developmental and Reproductive Toxicology (DART) Technical Committee
Dr. Dana Shuey, Endo Pharmaceuticals, Inc.
HESI Update Application of Genomics to Mechanism Based Risk Assessment
Dr. Cindy Afshari, Amgen Inc.
Immunotoxicology Technical Committee (ITC) Founded 1992
Dr. Ellen Evans, Schering-Plough Research Institute